Abzena Supplies Clinical Trial Material for Angiex’s AGX101 Study
Angiex’s Phase I clinical trial for AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC), is progressing with the support of clinical trial materials supplied by Abzena. This groundbreaking therapy focuses on targeting the blood vessels that feed aggressive tumors, making it a novel approach in oncology. The partnership between Angiex and Abzena ensures that AGX101 has the necessary resources to continue advancing through its early clinical stages.
Pipeline Review featured this development, highlighting the role Abzena plays in enabling cutting-edge clinical trials. The publication brings attention to how collaborations like this are critical for driving forward innovations in cancer treatment. As AGX101 moves ahead in clinical testing, the partnership showcases how biopharmaceutical companies can work together to accelerate progress in oncology.